COMPASS Pathways (CMPS) Projected to Post Earnings on Thursday

COMPASS Pathways (NASDAQ:CMPS) is expected to be announcing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

COMPASS Pathways Trading Down 2.5%

Shares of NASDAQ:CMPS opened at $6.34 on Thursday. The company has a market capitalization of $608.26 million, a P/E ratio of -3.45 and a beta of 2.21. COMPASS Pathways has a 1 year low of $2.25 and a 1 year high of $7.09. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82. The business’s 50 day simple moving average is $5.38 and its 200 day simple moving average is $4.40.

Institutional Investors Weigh In On COMPASS Pathways

A number of hedge funds have recently made changes to their positions in the stock. Nantahala Capital Management LLC boosted its stake in shares of COMPASS Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after purchasing an additional 1,350,698 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in COMPASS Pathways by 38.0% in the second quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock valued at $2,394,000 after buying an additional 235,345 shares in the last quarter. Acadian Asset Management LLC boosted its position in COMPASS Pathways by 42.0% in the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock valued at $686,000 after buying an additional 71,112 shares in the last quarter. Exome Asset Management LLC acquired a new stake in COMPASS Pathways in the second quarter valued at approximately $598,000. Finally, Royal Bank of Canada boosted its position in COMPASS Pathways by 49.8% in the first quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock valued at $256,000 after buying an additional 29,733 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on CMPS shares. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price target on shares of COMPASS Pathways in a research report on Friday, August 1st. HC Wainwright reduced their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Finally, BTIG Research increased their price target on shares of COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.